About this trial
A study to evaluate the safety, tolerability, and preliminary efficacy of DS010 in patients with cancer and cachexia
Eligibility criteria
Qualifiers
Subjects aged ≥ 18 years at screening;
Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures;
Able to provide written informed consent;
ECOG performance status score of 0, 1, or 2;
Disqualifiers
History of hypersensitivity or anaphylactic reaction to any therapeutic or diagnostic monoclonal antibody or molecules composed of monoclonal antibody components;
Presence of reversible decreased food intake, as determined by the investigator;
Receiving tube feeding or parenteral nutrition (total or partial parenteral nutrition) at screening;
Severe gastrointestinal disorders (including esophagitis, gastritis, malabsorption);
Trial design
Treatments tested in this trial
- DS010 injection
- DS010 injection
- DS010 injection
- DS010 injection
- DS010 injection
- DS010 injection
- DS010 injection
- DS010 injection
- DS010 injection
- DS010 injection
Treatment groups
10
Treatment groupsSee each treatment group below.